ArticleKidney international2009
Vasopressin in chronic kidney disease: an elephant in the room?
Article in Kidney international, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 59 citations in OpenAlex.
- Trial
- Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.Clinical journal of the American Society of Nephrology : CJASN · 2016Trial
- Article
- Article
- Article
- The role of age and sex in non-linear dilution adjustment of spot urine arsenic.BMC nephrology · 2024Article
- Low daily water intake profile-is it a contributor to disease?Nutrition and health · 2024Review
- Chronic Kidney Disease as a Comorbidity in Heart Failure.International journal of molecular sciences · 2023Review
- Kidney collecting duct cells make vasopressin in response to NaCl-induced hypertonicity.JCI insight · 2022Article
- Dysnatremias, Mortality, and Kidney Failure in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.Kidney medicine · 2022Article
- Chronic Lithium Therapy and Urine-Concentrating Ability in Individuals With Bipolar Disorder: Association Between Daily Dose and Resistance to Vasopressin and Polyuria.Kidney international reports · 2022Article
- ADPKD current management and ongoing trials.Journal of nephrology · 2020Review
- Cardiorenal Syndrome: Pathophysiology.Cardiology clinics · 2019Review
- The impact of daily temperature on renal disease incidence: an ecological study.Environmental health : a global access science source · 2017Article
- The Chronic Kidney Disease Water Intake Trial: Protocol of a Randomized Controlled Trial.Canadian journal of kidney health and disease · 2017Article
- Validation of Surrogates of Urine Osmolality in Population Studies.American journal of nephrology · 2017Article
- Association between fluid intake and kidney function, and survival outcomes analysis: a nationwide population-based study.BMJ open · 2016Observational
- Diabetes Complications in Childhood Diabetes-New Biomarkers and Technologies.Current pediatrics reports · 2015Article
- A review of the nonpressor and nonantidiuretic actions of the hormone vasopressin.Frontiers in medicine · 2015Review
- Early diabetic nephropathy in type 1 diabetes: new insights.Current opinion in endocrinology, diabetes, and obesity · 2014Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Perico et al. report that a dual arginine vasopressin (AVP) V(2) and V(1a) receptor antagonist lowers blood pressure, proteinuria, and glomerulosclerosis in 5/6 nephrectomized rats, pointing to its potential value in the treatment of chronic kidney disease (CKD). AVP likely contributes to CKD progression by its effects on renal hemodynamics, blood pressure, and mesangial and/or epithelial cells, but the relative contributions of V(2) and V(1a) receptors and potential usefulness of V(2) and V(1a) receptor antagonists remain ill defined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.